RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · IEX Real-Time Price · USD
1.151
-0.009 (-0.78%)
Jul 22, 2024, 10:05 AM EDT - Market open
RenovoRx Employees
RenovoRx had 8 employees as of December 31, 2023. The number of employees decreased by 1 or -11.11% compared to the previous year.
Employees
8
Change (1Y)
-1
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,006,375
Market Cap
27.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Dec 31, 2020 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Renalytix | 102 |
| Bolt Biotherapeutics | 100 |
| Enlivex Therapeutics | 71 |
| SAB Biotherapeutics | 57 |
| Surrozen | 42 |
| Palatin Technologies | 34 |
| Acasti Pharma | 32 |
| Brainstorm Cell Therapeutics | 29 |
RNXT News
- 14 days ago - RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist® - GlobeNewsWire
- 26 days ago - University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial - GlobeNewsWire
- 6 weeks ago - RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships - GlobeNewsWire
- 7 weeks ago - RenovoRx CEO Issues Update Letter to Shareholders - Business Wire
- 2 months ago - Publication of Results of Pre-Clinical Studies Support Efficacy and Drug Delivery Mechanism Potential of RenovoRx's TAMP™ Therapy Platform to Improve Targeted Cancer Drug Treatment Delivery - Business Wire
- 2 months ago - RenovoRx to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2024 - Business Wire
- 2 months ago - RenovoRx CEO Shaun R. Bagai to Present at the Aegis Capital Virtual Conference on May 9, 2024 - Business Wire
- 3 months ago - RenovoRx Regains Compliance with Nasdaq Stockholders' Equity Requirement - Business Wire